Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been reported to reduce macrovascular complications in people with type 2 diabetes and elevated cardiovascular risk.1 Using data from the same study programme, the authors have assessed the effect of canagliflozin among patients with and without a history of cardiovascular disease (secondary versus primary prevention).2
The study involved two trials that randomly assigned 10,142 participants with type 2 diabetes to canagliflozin or placebo.1, 2 …